News in Numbers

Moderna has announced plans to scrap five clinical programmes in a bid to save $1.1bn of R&D costs following years of declining revenues.

BioMarin Pharmaceuticals plans to let 225 staff members go.

Oncternal Therapeutics’ stock slumped by 60% after it announced plans to halt the development of two cancer candidates due to disappointing trial results.

Teva Pharmaceuticals has reached an $80m settlement with the city of Baltimore for its role in worsening the opioid epidemic.

The UK government has taken a significant step towards banning xylazine, commonly referred to as the “zombie drug”, and 21 other substances by introducing legislation.